latest news releases from the newsroom
Polydex Pharmaceuticals Limited
Analysis of Ushercell HIV Trials Reveals Difference in Seroconversion Groups Not Statistically Significant
TORONTO, July 25, 2007 (PRIME NEWSWIRE) -- Polydex Pharmaceuticals Limited (Nasdaq:POLXF) reports that today at the International AIDS Society 2007 Conference in Sydney Australia, Dr. Lut Van Damme of CONRAD, principal investigator of the Phase III clinical trial of Ushercell, reported further analysis of HIV results from the trial. The trial of Ushercell, a potential microbicide also known as cellulose sulfate, was halted in January of this year (see News Release January 31, 2007). Women who 'seroconverted' tested positive for HIV during the course of the clinical trials referred to herein.
Mass Connections Hires New Senior Vice President of Sales
CERRITOS, Calif., July 25, 2007 (PRIME NEWSWIRE) -- Mass Connections(r), the nation's leader in retail marketing, connecting brands with consumers -- in-store, online and in life -- announced today the addition of Mark Hyland as Senior Vice President of Sales. In this role, Mark will be responsible for overseeing and directing the sales organization to assure best in class service to current and prospective retail and CPG clients alike.
ATMI Reports Second Quarter Financial Results
DANBURY, Conn., July 25, 2007 (PRIME NEWSWIRE) -- ATMI, Inc. (Nasdaq:ATMI) today announced that revenues increased 12% to a record $92.4 million for the second quarter of 2007, compared with $82.5 million in the second quarter of 2006. Net income decreased 8% to $9.3 million, compared with $10.1 million a year ago, while earnings per diluted share were $0.26, compared with $0.27 per diluted share in the second quarter of 2006.